Hemab Therapeutics News and Activities

Acquisition, funding and merger involving Hemab Therapeutics.

• Hemab Therapeutics has just announced a $301 Million fundraising (posted on May 4 2026).
• Hemab Therapeutics has filed its IPO. Its stock ticker will be COAG. (posted on April 15 2026).
• Hemab Therapeutics has just announced a $157 Million fundraising (posted on October 27 2025).

View the org chart displaying its 25 main executives

Most searched biographies at Hemab Therapeutics

• Benny Sorensen, Chief Executive Officer and Director
• Jørgen Petersen, Director
• Laura Tadvalkar​, Director

Popular executive movements at Hemab Therapeutics

• Samarth Virk has joined the company as Senior Director, Digital Engagement  (posted on April 15 2026).
• Peter Fatum has joined the company as Vice President of Quality  (posted on December 18 2025).
• Anant Murthy has joined the company as Chief Operating Officer  (posted on September 9 2025).

Create your alert
to follow the executive moves at Hemab Therapeutics.

Hemab Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Hemab Therapeutics

Social media about Hemab Therapeutics

• Hemab Therapeutics on Wikipedia, Google News & Yahoo Finance
• Hemab Therapeutics on LinkedIn, X (Twitter) & YouTube